Abstract
Background Leishmaniasis, caused by Leishmania protozoan parasites transmitted by Phlebotomine sand flies, is a significant public health concern in the Mediterranean basin. Effective monitoring of Leishmania-infected sand flies requires standardized tools for comparing their distribution and infection prevalence. Consistent quantitative PCR (qPCR) conditions and efficient DNA extraction protocols are crucial for reliable results over time and across regions. However, there is currently a lack of technical recommendations for Leishmania DNA detection, which needs to be addressed. This study aimed to compare various DNA extraction protocols and conduct a qPCR based External Quality Assessment (EQA) through a multicenter study involving nine reference laboratories.
Methodology/Principal findings EQA samples were prepared using Leishmania infantum and L. major strains, at different concentration from 101 to 104 parasites/mL and distributed to participating centers. All centers, except one, detected all Leishmania concentrations, demonstrating diagnostic proficiency. The ability to detect low concentrations highlighted the robustness of the qPCR assay used, although Cq value variations suggested differences in sensitivity due to technical capabilities and/or extraction kit performances.
Reported comparative analysis of seven DNA extraction methods identified the EZ1 DSP Virus® Kit and QIAamp® DNA mini-kit as the most efficient, supporting their use for standardized protocols. The study also evaluated the impact of lyophilization and shipment conditions, finding no compromise in Leishmania detection, despite slight Cq value variations. In addition to EQA samples, experimentally infected sand fly have been included to mimic sample field condition. All centers detected positive samples, with variable Cq values, reflecting differences in individual infection load.
Conclusion and significance Overall, the study underscores the importance of standardized protocols and continuous quality assurance to maintain high diagnostic validity, crucial for effective surveillance of leishmaniasis, especially in field settings with low infection densities. Continuous training and calibration are essential to ensure uniform diagnostic performance across laboratories, enhancing epidemiological surveillance and disease control strategies.
Author Summary Leishmaniasis is a disease caused by Leishmania parasites, transmitted by sand flies, and poses a major health risk in the Mediterranean region. Monitoring the spread of nfected sand flies is crucial for controlling the disease. This study focused on improving the methods used to detect Leishmania in sand flies by comparing different DNA extraction techniques and assessing the accuracy of these methods across nine reference laboratories. All centers, except one, efficiently detected all Leishmania concentrations, demonstrating proficiency in diagnostic protocols. Moreover, we found that two specific DNA extraction kits, the EZ1 DSP Virus® Kit and QIAamp® DNA mini-kit, were the most effective for Leishmania detection. We also tested how sample preparation and shipping conditions affected the results, ensuring that our methods would work in real-world settings. Even under these conditions, the detection methods proved reliable. This work helps to standardize the detection of Leishmania, making surveillance more accurate and consistent. Continuous training and calibration are essential to ensure uniform diagnostic performance across laboratories, enhancing epidemiological surveillance and disease control strategies
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is co-funded by European Commission grant 101057690 and UKRI grants 10038150 and 10039289, and is catalogued by the CLIMOS Scientific Committee as CLIMOS number 011 (http://www.climos-project.eu). The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views of the European Commission, the Health and Digital Executive Agency, or UKRI. Neither the European Union nor granting authority nor UKRI can be held responsible. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. For the purposes of Open Access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The six Horizon Europe projects, BlueAdapt, CATALYSE, CLIMOS, HIGH Horizons, IDAlert, and TRIGGER, form the Climate Change and Health Cluster.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
All resources used in this article are provided in the article and all the analyses are detailed allowing the assessment or verification of the manuscript’s findings.
